ESTIMATION OF SALIVARY TUMOR NECROISIS FACTOR-ALPHA LEVEL IN PATIENTS WITH EROSIVE ORAL LICHEN PLANUS (A CASE CONTROL STUDY)

Document Type : Original Article

Authors

1 B.D.S (2003). Department of Oral Medicine, Periodontology, Oral Diagnosis and Radiology, Faculty of Dentistry, Alexandria University.

2 Professor at Department of Oral Medicine, Periodontology, Oral Diagnosis and Radiology, Faculty of Dentistry, Alexandria University.

3 Professor at Department of Oral Pathology, Faculty of Dentistry, Alexandria University.

4 - Professor and Head of Department of Biochemistry, Faculty of Medicine, Alexandria University.

Abstract

INTRODUCTION: Oral lichen planus (OLP) is a relatively common chronic inflammatory and a potentially malignant disorder of oral mucosa. Tumor necrosis factor-alpha (TNF- α) has been pointed as a key cytokine in OLP. OBJECTIVES: To evaluate whether the salivary levels of TNF- α were changed in patients with erosive oral lichen planus (EOLP). METHODOLOGY: A total of fourteen cases of EOLP with and without dysplastic changes, along with seven age matched healthy controls were included in this study. Samples of unstimulated saliva was collected, centrifuged and analyzed with enzyme linked immunosorbent assay (ELISA). RESULTS: There was a statistically significant increase in the salivary levels of TNF- α in patients of the two study groups when compared to the control group. CONCLUSIONS: TNF- α plays a role in pathogenesis and carcinogenesis of EOLP, and can be used as a useful marker and indicator for subjects at high risk to develop OLP as a potentially malignant lesion.

Keywords

Main Subjects

References

  1. Scrobota I, Mocan T, Catoi C, Bolfa P, Muresan A, Baciut G. Histopathological aspects and local implications of oxidative stress in patients with oral lichen planus. Rom J Morphol Embryol 2011; 52: 1305-9.
  2. Bajaj DR, Khoso NA, Devrajani BR, Matlani BL, Lohana P. Oral lichen planus: a clinical study. J Coll Physicians Surg Pak 2010; 20: 154-7.
  3. Daoud MS, Pittelkow MR. Lichen planus. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, LeffellDJ (eds). Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill, 2008. pp 244-12.
  4. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; 36: 575-80.
  5. Srinivas K, Aravinda K, Ratnakar P, Nigam N, Gupta S. Oral lichen planus - Review on etiopathogenesis. Natl J Maxillofac Surg 2011; 2: 15-6.
  6. Thornhill MH. Immune mechanisms in oral lichen planus. Acta Odontol Scand 2001; 59: 174-7
  7. Simark-Mattsson C, Bergenholtz G, Jontell M. Distribution of interleukin-2, -4, -10, tumor necrosis factor-alpha and transforming growth factor-b mRNAs in oral lichen planus. Arch Oral Biol 1999; 44: 499-507.
  8. Abram M, Vuckovic D, Wraber B, Doric M. Plasma cytokine response in mice with bacterial infection. Mediat Inflamm 2000; 9: 229-34.
  9. Nakao S, Kuwano T, Ishibashi T, Kuwano M, Ono M. Synergistic effect of TNF-alpha in soluble VCAM-1- induced angiogenesis through alpha 4 integrins. J Immunol 2003; 170: 5704-11.
  10. Scott KA, Moore RJ, Arnott CH. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003; 2: 445- 51.
  11. Sugermann PB, Savage NW, Seymour GJ, Wals LJ. Is there a role for tumor necrosis factor-alpha (TNFalpha) in oral lichen planus? J Oral Pathol Med 1996; 25: 219-24.
  12. Yammamoto T, Yoneda K, Ueta E, Osaki T. Serum cytokines, interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in oral disorders. Oral Surg Oral Med Oral Pathol 1994; 78: 727-35.
  13. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993; 694: 72-7.
  14. Taylor PC. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol 2001; 19: 153-68.
  15. Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning, 2013. p. 115. 
  16. Daly LE, Bourke GJ, McGilvray J. Statistical analysis. In: Interpretation and uses of medical statistics. 4th ed. Oxford: Scientific Publications(pub), 1991. p. 411-6.
  17. Mollaoglu N. Oral lichen planus: a review. Br J Oral Maxillofac Surg 2000; 38: 370-7.
  18. Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. A new classification for potentially malignant disorders of the oral cavity. Oral Oncol 2011; 47: 920-1.
  19. Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers-a new diagnostic tool for oral cancer. Clin Cancer Res 2006; 12: 3979-84.
  20. Nishanian R, Aziz N, Chung J, Detels R, Fahey JL. Oral fluids as an alternative to serum for measurement of markers on immune activation. Clin Diagn Lab Immunol 1998; 5: 507-12.
  21. Ghallab NA, el-Wakeel N, Shaker OG. Levels of salivary IFN-gamma, TNF-alpha, and TNF receptor-2 as prognostic markers in (erosive) oral lichen planus. Mediators Inflamm 2010; 2010: 847632.
  22. Juretić M, Cerović R, Belušić-Gobić M, Brekalo Pršo I, Kqiku L. Salivary levels of TNF-alpha± and IL-6 in patients with oral premalignant and malignant lesions. Folia Biol (Praha) 2013; 59: 99-102.
  23. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog 2005; 44: 77-82. 
  24. Saliou C, Kitazawa M, McLaughlin L, Yang JP, Lodge JK, Tetsuka T, et al. Antioxidants modulate acute solar ultraviolet radiationinduced NF-kappa-B activation in a human keratinocyte cell line. Free Radic Biol Med 1999; 26: 174-83.
  25. Dale BA. Fascination with epithelia. Architecture, proteins, and functions. J Dent Res 2003; 82: 866-9.
  26. Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, et al. NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008; 41: 144- 9.

Files

Share

How to cite

Statistics